Literature DB >> 20211905

Undiminished regulatory T cells in the thymus of patients with myasthenia gravis.

N Matsui1, S Nakane, F Saito, I Ohigashi, Y Nakagawa, H Kurobe, H Takizawa, T Mitsui, K Kondo, T Kitagawa, Y Takahama, R Kaji.   

Abstract

OBJECTIVE: The thymus has been implicated as a possible site of origin that triggers autoimmunity in myasthenia gravis (MG). Although several groups have suggested that the decrease in the number of regulatory T (Treg) cells contributes to the onset of MG, the exact role of Treg cells in MG remains unclear. To address this point, we examined the number and distribution of Treg cells in a large number of patients with MG.
METHODS: Immunohistofluorescence analysis of Foxp3 along with CD4 and CD8 was performed in thymic sections of MG (+) (n = 24) and MG (-) patients (n = 27). Circulating CD4(+)CD25(+) cells in the peripheral blood of patients with MG (n = 15) and age-matched healthy subjects (n = 15) were also analyzed.
RESULTS: Foxp3(+)CD4(+)CD8(-) cells were predominantly found in the thymic medulla and their number declined with age. There was no significant difference in the number or the distribution of Foxp3(+)CD4(+)CD8(-) cells in the thymus between MG (+) and MG (-) patients. The number of circulating CD4(+)CD25(+) cells in the peripheral blood of patients with MG was not significantly altered compared to that in healthy subjects.
CONCLUSION: The cellularity of Treg cells in the thymus and circulation is not diminished in patients with myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20211905     DOI: 10.1212/WNL.0b013e3181d31e47

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  B cells in the pathophysiology of myasthenia gravis.

Authors:  John S Yi; Jeffrey T Guptill; Panos Stathopoulos; Richard J Nowak; Kevin C O'Connor
Journal:  Muscle Nerve       Date:  2017-09-30       Impact factor: 3.217

2.  Comparison of Peripheral Blood Regulatory T Cells and Functional Subsets Between Ocular and Generalized Myasthenia Gravis.

Authors:  Jie Rao; Siyu Li; Qiyu Wang; Qi Cheng; Yu Ji; Wenwen Fu; Hui Huang; Ling Shi; Xiaorong Wu
Journal:  Front Med (Lausanne)       Date:  2022-06-09

Review 3.  Functional defect in regulatory T cells in myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Qin Li Jiang; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Ann N Y Acad Sci       Date:  2012-12       Impact factor: 5.691

4.  Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Balaji Ganesh; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Clin Immunol       Date:  2012-10-07       Impact factor: 3.969

5.  Characterization of CD4 and CD8 T cell responses in MuSK myasthenia gravis.

Authors:  J S Yi; A Guidon; S Sparks; R Osborne; V C Juel; J M Massey; D B Sanders; K J Weinhold; J T Guptill
Journal:  J Autoimmun       Date:  2013-12-28       Impact factor: 7.094

6.  Systems biology of myasthenia gravis, integration of aberrant lncRNA and mRNA expression changes.

Authors:  ZhaoHui Luo; Ye Li; XiaoFang Liu; MengChuan Luo; LiQun Xu; YueBei Luo; Bo Xiao; Huan Yang
Journal:  BMC Med Genomics       Date:  2015-03-18       Impact factor: 3.063

Review 7.  Animal models of myasthenia gravis: utility and limitations.

Authors:  Renato Mantegazza; Chiara Cordiglieri; Alessandra Consonni; Fulvio Baggi
Journal:  Int J Gen Med       Date:  2016-03-04

Review 8.  Immunoregulatory Cells in Myasthenia Gravis.

Authors:  Ying Wu; Jie Luo; Oliver A Garden
Journal:  Front Neurol       Date:  2020-12-15       Impact factor: 4.003

9.  FoxP3- Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines.

Authors:  Huanyu Meng; Shuyu Zheng; Qinming Zhou; Yining Gao; You Ni; Huafeng Liang; Sheng Chen
Journal:  Front Neurol       Date:  2021-12-17       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.